• KRRO is trading 7.04% down today at $12.80, reversing from a sharp multi-day rally.
  • This decline follows director share sales reported on June 23 and appears consistent with profit-taking.
  • The movement occurs alongside recent company-specific news, including the addition of KRRO-111 to the development pipeline for alpha-1 antitrypsin deficiency, progress on KRRO-121, and a Jones Trading upgrade to "Buy".